Cantor Fitzgerald analyst Eric Schmidt assumed coverage of Verastem (VSTM) with an Overweight rating and no price target The company is developing and commercializing drugs for Ras-driven cancers, the analyst tells investors in a research note. The firm thinks the shares are worth $15 based on a sum-of-the-parts valuation. The company’s avutometinib and defactinib looks like a better and more tolerable drug than the MEK inhibitors that are used off-label in recurrent low-grade serous ovarian cancer, contends Cantor.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VSTM:
- Verastem’s Promising KRAS G12D Inhibitor VS-7375: A Buy Rating Backed by Strong Clinical Data and Strategic Outlook
- Leerink says competitor data suggest promising view for Revolution’s zoldonrasib
- Verastem Updates on Cancer Therapy Developments
- Verastem’s Promising Phase 3 Trial in Ovarian Cancer: A Potential Game-Changer?